CAN PCI BE IMPROVED TO TREAT ANGINA IN STABLE PATIENTS?

Prof Amir Lerman Is an endowed named Barbara Lips professor of medicine and a consultant in the department of cardiovascular disease at the Mayo graduate school of medicine. Prof. Lerman graduated from the Technion school of Medicine in Haifa Israel and completed his training in internal medicine, cardiovascular diseases and invasive cardiology at the Mayo Clinic Prof. Lerman serves as an associate chair of the department of Cardiovascular medicine and the Director of the Mayo Clinic cardiovascular research center, the medical director of the chest pain and coronary physiology clinic. Prof. Lerman’s interest is the coronary physiology and imaging and the role of novel therapy of the microcirculation and endothelial function in cardiovascular diseases. Prof. Lerman’s research program is also active and publishes in the area regenerative medicine, innovative technologies and digital health. Prof. Lerman published more than 800 manuscripts, book chapters and reviews; the NIH, AHA, and several foundations support his research.

Prof Andrew Sharp qualified from Edinburgh Medical School in 1998 and is Professor of Cardiology at the University Hospital of Wales and Cardiff University in the U.K. He conducted his early training at the Royal Infirmary of Edinburgh, before moving to London for his senior clinical training. He completed the prestigious Milan-Imperial Interventional Cardiology Fellowship programme, having spent a year in San Raffaele and Columbus Hospitals, Milan, Italy, under the tutelage of Professor Antonio Colombo. He also spent three years training in interventional cardiology at Imperial College Hospitals in London. Prof Sharp was awarded an MD postgraduate research degree from the University of Edinburgh for his work on the hypertensive heart and his research interests include intracoronary imaging and physiology. as well as the use of device-based treatments for hypertension and pulmonary embolism.

Dr Breda Hennessey graduated from the Third Faculty of Medicine in Charles University in Prague. Following this, she returned to Ireland to complete her general medical and higher specialist cardiology training. In 2019, she was awarded the Brian McGovern Scholarship by the Irish Cardiac Society, and this allowed her to commence her subspecialty training in Interventional Cardiology at Hospital Clínico San Carlos in Madrid. She completed a two-year coronary interventional fellowship, with a focus on intracoronary imaging, invasive physiology and ultra-low dose contrast intervention. Following completion of her coronary training, she undertook a further fellowship in structural intervention, also at Hospital Clínico San Carlos. In addition to her clinical work, she has been involved in various research projects pertaining to ultra-low dose contrast PCI, investigating the impact of new technologies in reducing contrast burden in complex PCI . She has authored and co-authored a number of research articles, book chapters and has contributed to the European association of Percutaneous Cardiovascular Interventions textbook. During her time at Hospital Clinico San Carlos, she completed a Masters in Interventional Cardiology and is currently undertaking a PHD at the Complutense University of Madrid with a focus in ultra-low dose contrast PCI. Throughout her fellowship, she regularly took part in the preparation and delivery of educational courses, both at Hospital Clinico San Carlos and in collaboration with other tertiary referral centres and international cardiology societies in Spain, the UK and the UAE.

Dr. Hernán Mejía-Rentería is an Interventional Cardiologist at the Department of Cardiology, Hospital Clinico San Carlos, Madrid, Spain. He graduated from the Medical School of Universidad del Valle (Colombia) and underwent specialty training in Cardiology at Hospital Clinico San Carlos, Madrid, Spain. Subsequently, he completed his subspecialty training as Interventional Cardiologist in 2017 at the same institution. Dr. Mejía-Rentería obtained a PhD (Cum Laude) in coronary physiology in 2021 at Universidad Complutense de Madrid. He is a member of European Association of Percutaneous Cardiovascular Interventions (EAPCI) and has published over 70 indexed scientific articles on coronary physiology, functional angiography, intracoronary imaging techniques and Takotsubo Syndrome, and is author of chapters in different academic textbooks. His main research areas at present include coronary physiology assessment with invasive and angiography derived techniques in patients with coronary artery disease or ischemia with non-obstructive coronary arteries.

Dr Justin Davies is a board member of Monaco Cardio at the Princess Grace Hospital, Monaco, and an interventional cardiologist with over 15 years of experience as a leading educator in the field. His clinical and academic career was established at Hammersmith Hospital, Imperial College London, where he built an international reputation for innovation in cardiovascular medicine. Over the course of his career, he has successfully mentored 15 PhD students, published more than 500 peer-reviewed papers — including landmark studies in the New England Journal of Medicine and The Lancet — and holds 20 patents in cardiovascular medicine and technology. He was the co-principal investigator of the DEFINE-FLAIR study, which helped establish iFR (Instantaneous Wave-Free Ratio), a diagnostic technique he invented, as a globally adopted standard in coronary physiology. His work reflects a unique blend of scientific innovation, academic leadership, and clinical excellence. In addition to his research and academic commitments, Justin is CEO of Cerebria AI, where he leads the development of next-generation AI-powered cardiovascular imaging and physiology tools. Under his leadership, Cerebria AI is advancing cutting-edge solutions that integrate artificial intelligence with frontline cardiology to enhance clinical decision-making and patient outcomes. Combining deep clinical expertise with entrepreneurial vision, he continues to guide international ventures through funding, regulatory pathways, and commercialization, while remaining committed to transforming cardiovascular care on a global scale.

Dr. Marco Lombardi is an interventional cardiologist at the Azienda Ospedaliero-Universitaria of Alessandria, Italy. He obtained his medical degree from Campus Bio-Medico University of Rome in 2018. He completed his cardiology residency at the Catholic University of the Sacred Heart (Rome, Italy) and pursued an interventional cardiology fellowship at Hospital Clínico San Carlos / Complutense University (Madrid, Spain). Dr. Lombardi also served as a research fellow at the VCU Pauley Heart Center (Richmond, USA) and is currently completing a PhD at the University of Genoa (Genoa, Italy). His main research interests focus on complex PCI, intracoronary physiology and imaging.

Dr Tim Schäufele is an interventional cardiologist with special interest in CTOs, coronary physiology and calcified lesions. He is owner of Kardiologie-Innenstad Bern private practice and Interventional Cardiologist at Lindenhofspital Bern. Prior to this, he served as Head of Cathlab and Interventional Cardiology at Robert-Bosch-Krankenhaus Stuttgart, after serving as a Research Fellow in Cardiac Magnetic Imaging at the Department of Cardiology University Heidelberg. Dr Schäufele is a Co-Founding Member of Transradial Workingroup German Cardiac Society, a Board Member of the Interventional Working Group of the German Cardiac Society, and a Full Member EuroCTO Club.